Stomach microbiota, *Helicobacter pylori*, and group 2 innate lymphoid cells

Hiroshi Ohno and Naoko Satoh-Takayama

**Abstract**

The stomach has been thought to host few commensal bacteria because of the existence of barriers, such as gastric acid. However, recent culture-independent, sequencing-based microbial analysis has shown that the stomach also harbors a wide diversity of microbiota. Although the stomach immune system, especially innate lymphoid cells (ILCs), has not been well elucidated, recent studies have shown that group 2 ILCs (ILC2s) are the dominant subtype in the stomach of both humans and mice. Stomach ILC2s are unique in that their existence is dependent on stomach microbiota, in sharp contrast to the lack of an impact of commensal microbiota on ILC2s in other tissues. The microbiota dependency of stomach ILC2s is partly explained by their responsiveness to interleukin (IL)-7. Stomach ILC2s express significantly higher IL-7 receptor protein levels on their surface and proliferate more in response to IL-7 stimulation in vitro than small intestinal ILC2s. Consistently, the stomach expresses much higher IL-7 protein levels than the small intestine. IL-5 secreted from stomach ILC2s promotes immunoglobulin (Ig) A production by plasma B cells. In a murine model, stomach ILC2s are important in containing *Helicobacter pylori* infection, especially in the early phase of infection, by promoting IgA production.

**Introduction**

The surfaces of an animal’s body, such as the skin and mucosa, provide a boundary between the body and the surrounding environment and are colonized by numerous commensal bacteria, called microbiota. In particular, the intestinal mucosa hosts the largest microbial community, of 40 trillion bacteria, in the body. Gut microbiota contribute to gut maturation, host nutrition, and pathogen resistance. By contrast, it has been thought that there are fewer commensal bacteria in the stomach due to the characteristic feature of the gastric barrier, such as the highly acidic conditions of the lumen due to acid-secreting parietal cells and the presence of proteolytic enzymes (pepsins) from pepsinogen-secreting zymogenic chief cells. The impact of gastric microbiota on host pathophysiology is not well understood compared to the microbiota of the intestine. Compared to the intestine, where evidence has accumulated that it has evolved the unique gut-associated immune system to deal with gut microbiota and orally ingested pathogens, studies on the stomach immune system are less common. However, recent studies have shown that wide bacterial diversity can be found in the human stomach as well.

Here, we will review the recently identified characteristics of stomach group 2 innate lymphoid cells (ILC2s), especially their relationship with gastric microbiota and *Helicobacter pylori* infection.

**Stomach and microbiota**

Recent culture-independent analyses of microbial composition with 16S rRNA sequencing have shown wide bacterial diversity in the human stomach. In individuals who have neither of the two major gastric microbiota-perturbing events, *H. pylori* infection nor proton pump inhibitor (PPI) usage, it has been shown that the microbiota in the stomach (and the duodenum)
possesses a significantly lower number of bacteria than that of the lower gastrointestinal tract, which is probably correlated with the lower luminal pH in these organs. The major phyla are Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria throughout the human gastrointestinal tract. In contrast to the lower intestinal tract (and feces), where Firmicutes are dominant, followed by Bacteroidetes, Streptococcus and Prevotella are the two major genera detected in the stomach, which are minor genera in human feces, considered to reflect their decreased presence in the lower gastrointestinal tract.

Gastric-microbiota-modulating factors: H. pylori and PPIs

As mentioned above, H. pylori infection perturbs the gastric microbiota. H. pylori is a Gram-negative bacterium categorized as a pathobiont bacteria that colonizes the gastric mucosa of half or more of the human population in the world, ranging from 20% in developed countries to >90% in developing countries. H. pylori colonizes the gastric mucosa using virulence properties, such as vacuolating cytotoxin, VacA and cytotoxin-associated gene A, cagA, and causes acute and chronic gastritis, eventually progressing to more severe disorders, including peptic ulcer disease and gastric cancer.

H. pylori needs to overcome harsh acidic conditions in the stomach lumen to colonize and establish infection in the stomach. It has been well documented that H. pylori infection occurs in early childhood, but rarely in adults. H. pylori infection is basically acquired in childhood and persists throughout life without eradication therapy. One of the possible explanations is that the ontogenetic development of the stomach in early childhood life is thought to be associated with the alleviation of gastric hostility, including achlorhydria, compared to adulthood. Gastric hostility in adults sufficiently inhibits H. pylori infection. Therefore, H. pylori infection rarely occurs in adulthood, and when it does, it likely causes acute gastritis and is then eradicated. H. pylori possesses urease and other enzymes that produce ammonia, which aid its infection by increasing the pH.

Chronic H. pylori infection causes atrophic gastritis with a loss of parietal cells. This leads to increased gastric pH and could modulate the gastric microbiota. The impact of H. pylori infection on the gastric microbiota has been studied. Although the majority of the gastric microbiota is occupied by H. pylori, its presence does not largely affect the composition of the gastric community. H. pylori infection-associated gastric microbiota dysbiosis has been implicated in the pathogenesis of gastric disorders, but the understanding of the complex interaction between the microbiota and H. pylori still needs to be further addressed in the development of gastric diseases.

PPIs are another gastric microbiota modifier. PPIs suppress gastric acid secretion, are among the most commonly prescribed drugs and are widely used to treat gastric acid-related disorders, such as gastroesophageal reflux disease and peptic ulcers. PPIs reduce bacterial gastric acid secretion and lead to a significant change in the overall microbiota composition. In the stomach, with PPI treatment, a greater diversity of bacterial species is observed, and the relative abundance of the phyla Firmicutes and Fusobacteria (whose abundance is very small without PPIs) is increased.

ILCs and gut microbiota

ILCs are largely classified into three groups based on the characteristic expression of transcription factors and cytokine production (Fig. 1). ILC1s used to include all ILCs producing interferon-γ; however, it is now common to say that ILC1s are distinct from NK cells, whose differentiation is regulated by E4BP4 and Eomes. ILC3s are known to produce interleukin (IL)-17 and IL-22 upon stimulation with IL-1β or IL-23; they are subdivided into (i) lymphoid tissue-inducer cells, which express CCR6 and possess lymphoid tissue-inducing ability; (ii) NKP46-ILC3s, which express NKP46 (also called natural cytotoxicity receptor 1); and (iii) CCR6- NKP46-ILC3s, which do not belong to (i) and (ii). ILC3s are basically distributed in tissues facing the external environment, especially the gastrointestinal tract, and play a role in defense mechanisms against pathogens. Although the relationship between ILCs and gut microbiota has not been well understood until recently, recent advances in ILC biology, including single-cell analysis, have unveiled the details of the relationship.

ILC2s in physiology and pathology

ILC2s were independently identified in 2010 by three groups. ILC2s produce type 2 cytokines, such as IL-5, IL-9, and IL-13, upon stimulation with IL-25, IL-33 or TSLP, and are involved in the eradication of parasite infection. Recent studies have attracted attention on ILC2s by showing that these cells are involved in the pathogenesis of diseases, including fibrosis, asthma, and obesity. In these diseases, the common scheme of pathogenesis is that an alarmin, IL-33, released upon epithelial cell damage by allergens, inflammation, or stress responses, triggers the activation of ILC2s. IL-33-activated ILC2s secrete IL-4, IL-5, and IL-9, which, in turn, induce eosinophils and activate mast cells, while IL-13 from ILC2s induces fibrosis. In addition, it has been reported that ILC2s produce not only cytokines, but also opioid methionine-enkephalin peptides to regulate adipose function and metabolic homeostasis by acting directly on
adipocytes. In contrast to ILC3s, commensal microbiota do not seem to be involved in the induction or differentiation of ILC2s. These observations were made with ILC2s in adipose tissues, the intestine, and the lung, which is in sharp contrast to the microbiota dependency observed with stomach ILC2s as described below.

**ILC2s and stomach microbiota**

Studies on ILCs have mostly been performed in the intestine and lung, but information on the distribution and function of ILCs in the stomach is still lacking. We have recently examined ILC subsets in the murine stomach. In the stomach, ILC2s are dominant, with a few ILC1s, and the stomach is almost devoid of ILC3s. This distribution is in sharp contrast to that observed in the intestine, where comparable numbers of the three ILC subsets exist. ILC2 dominance in the stomach has also been reported in humans.

More importantly, ILC2s existing in the stomach are dependent on stomach microbiota, unlike ILC2s in the other tissues/organisms. In germ-free (GF) mice, the number of stomach ILC2s was significantly decreased (Fig. 2). This observation is also in sharp contrast to that observed in the intestine, where the number of ILC2s is not affected by a lack of a microbiota, as seen in GF mice.

Our findings indicate that stomach ILC2s possess unique characteristics compared to their counterparts in other tissues. In fact, stomach ILC2s express significantly higher IL-7R levels on their surface and proliferate more in response to IL-7 stimulation than ILC2s in vitro. Consistently, the stomach expresses much higher IL-7 protein levels than the small intestine. Interestingly, the expression of IL-7 in stomach tissue is hardly detected under GF conditions. In addition, IL-7R expression on stomach ILC2s is also dependent on the existence of stomach microbiota, at least partly explaining the microbiota dependency of stomach ILC2s. In contrast, the expression of the IL-33 receptor on stomach ILC2s is comparable, and that of IL-33 in the stomach tissue is slightly decreased in GF compared to specific pathogen-free (SPF) conditions (Fig. 2).

Immunoglobulin (Ig) A coats the surface of commensal bacteria to prevent them from attaching to and invading the intestinal epithelium. With the help of cytokines, B cells undergo class switch recombination to become different classes of Ig-producing B cells. In the case of IgA, IL-4 regulates class switching of B cells from IgM to IgA, and IL-5 further promotes the differentiation of IgA-expressing B cells to IgA-secreting plasma cells. Although T helper (Th) 2 cells are the main source of IL-5, ILC2s have recently been established as another source of robust IL-5 secretion. We have shown that microbiota-induced ILC2s are required as a major source of IL-5 for the induction of IgA+ plasma B cells, as...
well as efficient IgA secretion from these cells in the stomach (Fig. 2)\textsuperscript{42}. The secreted IgA could modulate stomach microbiota composition by coating its subset. Among stomach microbiota, members of the \textit{S24-7} family within the order \textit{Bacteroidales} are suggested to be candidate bacteria for ILC2 induction\textsuperscript{42}. Our preliminary results indicate that there seems to be differential ILC2-inducing ability among several \textit{S24-7} clones, and further studies should clarify the molecular mechanisms underlying bacterial induction of stomach ILC2s.

PPIs suppress gastric acid secretion and are among the most commonly prescribed drugs, widely used to treat gastric acid-related disorders, such as gastroesophageal reflux disease and peptic ulcer and, sometimes, \textit{H. pylori} infection\textsuperscript{23,24}. PPIs reduce bactericidal gastric acid secretion and lead to a significant change in the overall microbiota composition\textsuperscript{11,23}. In the stomach, with PPI treatment, a greater diversity of bacterial species is observed, and the relative abundance of the phyla \textit{Firmicutes} and \textit{Fusobacteria} (whose abundance is very small without PPIs) is increased\textsuperscript{11}. This change in gastric microflora composition might affect the number of ILC2-inducible bacteria and, thus, the number of ILC2s in the stomach, which, in turn, can alter the composition of the gastric microbiota.

**Stomach ILC2s and \textit{H. pylori} infection**

\textit{H. pylori} infection, especially in the acute phase, is accompanied by a mucosal IgA response, although the T-cell response is predominantly Th1 type\textsuperscript{16,47,48}. In a murine \textit{H. pylori} infection model, we recently identified that stomach ILC2s are the source of IL-5 for IgA production in the early phase of \textit{H. pylori} infection (Fig. 3)\textsuperscript{42}. The expansion of IL-5-receptor-expressing plasmablasts is initiated by ILC2 activation, which is indispensable to restrain \textit{H. pylori} infection. This is also supported by the fact that a significant reduction in plasma B cells and plasmablasts, as well as a reduction in \textit{H. pylori} coated with IgA, was observed in mice with ILC2-specific deficiency. IgA-mediated \textit{H. pylori} elimination has a strong correlation with the restraint of gastric inflammation, which is prominently diminished in mice lacking ILC2s\textsuperscript{42}. It has also been shown that the Th2 cell-dependent IgA response is induced for mucosal protection in the late phase of infection (Fig. 3)\textsuperscript{42}. 

---

**Fig. 2 Stomach ILC2s.** In germ-free (GF) mice, there are few ILC2s. Under GF conditions, IL-7 expression in stomach tissue is hardly detectable, and IL-7 receptor expression on stomach ILC2s is lower than that under SPF conditions. In contrast, the expression of the IL-33 receptor on stomach ILC2s is similar and that of IL-33 in the stomach tissue is slightly decreased in GF compared to SPF conditions. Under SPF conditions, the combination of IL-33 and IL-7 signaling leads to IL-5 secretion by ILC2s, which then promotes IgA production from plasma B cells. 

---

\textsuperscript{42} Ohno and Satoh-Takayama \textit{Experimental & Molecular Medicine} (2020) 52:1377–1382
As mentioned above, *H. pylori* infection is often acquired in childhood and persists throughout life without eradication therapy\(^4^4,4^6\), while *H. pylori* infection rarely occurs in adulthood, and when it does, it causes acute gastritis and is then eradicated\(^4^7,4^8\). Since early childhood is a particularly vulnerable period as the immune system is still developing, one bold hypothesis is that not enough ILC2 development occurs to eradicate *H. pylori* infection in childhood, although there is no evidence to support this notion at this time; further studies are awaited to clarify whether this hypothesis is true.

**Conclusion**

It is now clear that the stomach is not a totally sterile and immunologically silent organ, but instead harbors a wide diversity of commensal microbiota with unique composition and a unique immune system within the gastrointestinal tract. In particular, it possesses ILC2s with characteristics that are distinct from their counterparts in other organs/tissues. The stomach ILC2s are dependent on the presence of stomach microbiota, and they can modulate the composition of the microbiota by promoting IgA production. Stomach ILC2s are also important in *H. pylori* infection. *H. pylori* can evade or disturb innate and adaptive immune responses via multiple mechanisms to establish chronic infection, leading to clinical gastroduodenal disorders, including chronic gastritis, peptic ulcers, and two malignancies—gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. Therefore, it is important to understand the stomach immune system, including ILC2s, in more detail to develop novel treatment strategies to contain its infection.
10. Li, X. X. et al. Bacterial microbiota profiling in gastritis without Helicobacter pylori infection or non-steroidal anti-inflammatory drug use. PLoS ONE 4, e7985 (2009).

11. Mailhe, M. et al. Repertoire of the gut microbiota from stomach to colon using culturomics and next-generation sequencing. BMC Microbiol. 18, 157 (2018).

12. Nishijima, S. et al. The gut microbiome of healthy Japanese and its microbial and functional uniqueness. DNA Res. 23, 125–133 (2016).

13. Rhee, K. H., Park, J. S. & Cho, M. J. Helicobacter pylori: bacterial strategy for incipient stage and persistent colonization in human gastric niches. Yonsei Med. J. 55, 1453–1466 (2014).

14. Fox, J. G. & Wang, T. C. Inflammation, atrophy, and gastric cancer. J. Clin. Invest. 117, 60–69 (2007).

15. Camilo, V., Sugiyama, T. & Touati, E. Pathogenesis of Helicobacter pylori infection. Helicobacter 22, 1 (2017).

16. Reyes, V. E. & Peniche, A. G. Helicobacter pylori deregulates T and B cell signaling to trigger immune evasion. Curr. Top. Microbiol. Immunol. 421, 229–265 (2019).

17. Banatvala, N. et al. The cohort effect and Helicobacter pylori. J. Infect. Dis. 168, 219–229 (1993).

18. Koda, Y. K., Laudanna, A. A. & Barbieri, D. Variation and physiological significance of basal gastrinemia in normal children. Arq. Gastroenterol. 29, 66–70 (1992).

19. Kuipers, E. J. et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 345, 1525–1528 (1995).

20. Marshall, B. Helicobacter pylori: 20 years on. Clin. Med. 2, 147–152 (2002).

21. Coker, O. O. et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut 67, 1024–1032 (2018).

22. Ferreira, R. M. et al. Gastric mucosal microbrial community profiling reveals a dysbiotic cancer-associated microbiota. Gut 67, 226–236 (2018).

23. Eusebi, L. H. et al. Proton pump inhibitors: risks of long-term use. J. Gastroenterol. Hepatol. 32, 1295–1302 (2017).

24. Haaxstrup, P. F., Thompson, W., Sonderegard, J. & Jarbo, D. E. Side effects of long-term proton pump inhibitor use: a review. Basic Clin. Pharmac. Toxicol. 123, 114–121 (2018).

25. Vivier, E. et al. Innate lymphoid cells: 10 years on. Nat. Rev. Immunol. 12, 1045–1054 (2011).

26. Ricardo-Gonzalez, R. R. et al. Tissue signals imprint ILC2 identity with anticipatory function. Nat. Immunol. 19, 1093–1099 (2018).

27. Satoh-Takayama, N. et al. Bacteria-induced group 2 innate lymphoid cells in the stomach provide immune protection through induction of IgA immunity. J. Exp. Med. 218 (2017).

28. Li, R. et al. Group 2 innate lymphoid cells are involved in skewed type 2 immunity of gastric diseases induced by Helicobacter pylori infection. J. Exp. Med. 207, 1471–1486 (2020).

29. Porte, J. J. et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464, 1367–1370 (2010).

30. Hams, E. et al. IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis. Proc. Natl Acad. Sci. USA 111, 367–372 (2014).

31. Moretti, S. et al. A mast cell–ILC2–Th9 pathway promotes lung inflammation in cystic fibrosis. Nat. Commun. 8, 6807 (2017).

32. Ealey, K. N., Moro, K. & Kayau, S. Are ILC2s Jekyll and Hyde in airway inflammation? Immunol. Rev. 278, 207–218 (2017).

33. Brestoff, J. R. et al. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature 519, 242–246 (2015).

34. Sasaki, T. et al. Innate lymphoid cells in the induction of obesity. Cell Rep. 28, 202–217.e207 (2019).

35. Halm, T. Y. et al. Group 2 innate lymphoid cells are critical for the induction of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity 40, 425–435 (2014).

36. Noval Rivas, M., Burton, O. T., Oettgen, H. C. & Chatila, T. IL-4 production by group 2 innate lymphoid cells promotes food allergy by blocking regulatory T-cell function. J. Allergy Clin. Immunol. 138, 801–811.e809 (2016).

37. Pelly, V. S. et al. IL-4-producing ILC2s are required for the differentiation of TH2 cells following Heligmosomoides polygyrus infection. Mucosal Immunol. 9, 1407–1417 (2016).

38. Monticelli, L. A. et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat. Immunol. 12, 1045–1054 (2011).

39. Kusumoto, D. Y., Hiramin, G. R. & Strober, W. Regulation of IgA differentiation in CH12LX B cells by lymphokines. IL-4 induces membrane IgM-positive CH12LX cells to secrete IgA. J. Immunol. 141, 713–720 (1988).

40. Guram, R. K. & Zhu, J. Orchestration between ILC2s and TH2 cells in shaping type 2 immune responses. Cell Mol. Immunol. 16, 225–235 (2019).

41. Sobala, G. M. et al. Acute Helicobacter pylori infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. Gut 32, 1415–1418 (1991).

42. Mattapallil, J. J., Dandelier, S., Canfield, D. R. & Solnick, J. V. A predominant TH1 type of immune response is induced early during acute Helicobacter pylori infection in rhesus macaques. Gastroenterology 118, 307–315 (2000).